Unknown

Dataset Information

0

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.


ABSTRACT: Previous data suggest that the response of chronic myeloid leukemia cells to imatinib is dose-dependent. The potential benefit of initial dose intensification of imatinib in pre-treated patients with chronic phase chronic myeloid leukemia remains unknown.Two hundred and twenty-seven pre-treated patients with chronic myeloid leukemia in chronic phase were randomly assigned to continuous treatment with a standard dose of imatinib (400 mg/day; n=113) or to 6 months of high-dose induction with imatinib (800 mg/day) followed by a standard dose of imatinib as maintenance therapy (n=114).The rates of major and complete cytogenetic responses were significantly higher in the high-dose arm than in the standard-dose arm at both 3 and 6 months (major cytogenetic responses: 36.8% versus 21.2%, P=0.01 and 50.0% versus 34.5%, P=0.018; complete cytogenetic responses: 22.8% versus 6.2%, P<0.001 and 40.4% versus 16.8%, P<0.001) on the basis of an intention-to-treat analysis. At 12 months, the difference between treatment arms remained statistically significant for complete cytogenetic responses (40.4% versus 24.8%, P=0.012) but not for major cytogenetic responses (49.1% versus 44.2%, P=0.462). The rate of major molecular responses was also significantly better at 3 and 6 months in the high-dose arm (month 3: 14.9% versus 3.5%, P=0.003; month 6: 32.5% versus 8.8%, P<0.001). Overall and progression-free survival rates were comparable between arms, but event-free survival was significantly worse in the high-dose arm (P=0.014).Standard-dose imatinib remains the standard of care for pre-treated patients with chronic phase chronic myeloid leukemia (Clinicaltrials.gov identifier: NCT00327262).

SUBMITTER: Petzer AL 

PROVIDER: S-EPMC3487557 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.

Petzer Andreas L AL   Fong Dominic D   Lion Thomas T   Dyagil Irina I   Masliak Zvenyslava Z   Bogdanovic Andrija A   Griskevicius Laimonas L   Lejniece Sandra S   Goranov Stefan S   Gercheva Liana L   Stojanovic Aleksandar A   Peytchev Dontcho D   Tzvetkov Nikolay N   Griniute Rasa R   Stanchev Atanas A   Grubinger Thomas T   Kwakkelstein Marthin M   Schuld Peter P   Gastl Guenther G   Wolf Dominik D  

Haematologica 20120417 10


<h4>Background</h4>Previous data suggest that the response of chronic myeloid leukemia cells to imatinib is dose-dependent. The potential benefit of initial dose intensification of imatinib in pre-treated patients with chronic phase chronic myeloid leukemia remains unknown.<h4>Design and methods</h4>Two hundred and twenty-seven pre-treated patients with chronic myeloid leukemia in chronic phase were randomly assigned to continuous treatment with a standard dose of imatinib (400 mg/day; n=113) or  ...[more]

Similar Datasets

| S-EPMC9252917 | biostudies-literature
| S-EPMC4445370 | biostudies-literature
| S-EPMC6373759 | biostudies-literature
| S-EPMC5655928 | biostudies-literature
| S-EPMC5345391 | biostudies-literature
| S-EPMC6119151 | biostudies-literature
| S-EPMC4979200 | biostudies-literature
| S-EPMC9310209 | biostudies-literature
| S-EPMC5157124 | biostudies-literature
| S-EPMC9950928 | biostudies-literature